Tianda Pharmaceuticals Income Statement

Financials in millions HKD. Fiscal year is January - December.

Millions HKD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Mar '22 Mar 31, 2022
Revenue	322.95	329.94	532.09	546.69	509.96
Revenue Growth (YoY)	-2.12%	-37.99%	-2.67%	7.20%	7.51%
Cost of Revenue	189.64	177.91	276.56	295.17	268.73
Gross Profit	133.31	152.02	255.53	251.52	241.22
Selling, General & Admin	179.07	192.89	271.45	285.52	269.46
Research & Development	8.33	13.28	13.11	36.15	15.86
Operating Expenses	187.4	206.17	284.56	321.67	285.32
Operating Income	-54.09	-54.15	-29.02	-70.14	-44.1
Interest Expense	-3.53	-4.85	-4.95	-6.72	-0.73
Interest & Investment Income	-	1.1	3.03	4.34	2.3
Currency Exchange Gain (Loss)	-	-0.11	0.48	-0.21	1.07
Other Non Operating Income (Expenses)	3.06	4.48	4.91	6.93	2.32
EBT Excluding Unusual Items	-54.57	-53.54	-25.55	-65.8	-39.13
Impairment of Goodwill	-14.76	-1.34	-	-	-1.58
Gain (Loss) on Sale of Investments	-	0.64	-0.29	0.7	0.67
Gain (Loss) on Sale of Assets	-	-0.1	0.14	1.25	12.03
Pretax Income	-69.33	-54.34	-25.69	-63.85	-28.02
Income Tax Expense	0.93	7.07	-0.69	-4.86	-6.34
Earnings From Continuing Operations	-70.25	-61.41	-25.01	-58.99	-21.68
Minority Interest in Earnings	0.26	0.04	0.85	4.35	1.9
Net Income	-70	-61.37	-24.16	-54.64	-19.77
Net Income to Common	-70	-61.37	-24.16	-54.64	-19.77
Shares Outstanding (Basic)	2,150	2,150	2,150	2,150	2,150
Shares Outstanding (Diluted)	2,150	2,150	2,150	2,150	2,150
EPS (Basic)	-0.03	-0.03	-0.01	-0.03	-0.01
EPS (Diluted)	-0.03	-0.03	-0.01	-0.03	-0.01
Free Cash Flow	-	-30.3	-99.04	68.63	-61.98
Free Cash Flow Per Share	-	-0.01	-0.05	0.03	-0.03
Dividend Per Share	-	-	0.003	0.003	0.003
Dividend Growth	-	-	-25.01%	33.35%	-
Gross Margin	41.28%	46.08%	48.02%	46.01%	47.30%
Operating Margin	-16.75%	-16.41%	-5.46%	-12.83%	-8.65%
Profit Margin	-21.68%	-18.60%	-4.54%	-9.99%	-3.88%
Free Cash Flow Margin	-	-9.18%	-18.61%	12.55%	-12.16%
EBITDA	-24.41	-24.47	-0.95	-27.88	-29.64
EBITDA Margin	-7.56%	-7.42%	-0.18%	-5.10%	-5.81%
D&A For EBITDA	29.68	29.68	28.07	42.26	14.46
EBIT	-54.09	-54.15	-29.02	-70.14	-44.1
EBIT Margin	-16.75%	-16.41%	-5.45%	-12.83%	-8.65%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.